NOTCH1 and acute lymphoblastic leukemia: For example, mice treated with anti-Notch1-treated mice were healthy or had low leukemia burden compared to control animals, suggesting decreased LSC function.111 Preliminary results from the phase I clinical trial on OMP-52M51 in patients with hematologic malignancies, including T-ALL, suggest a moderate efficacy and an acceptable safety profile, with diarrhea noted as the most common side effect.112